Femasys Inc. (FEMY)
NASDAQ: FEMY · Real-Time Price · USD
0.3598
+0.0148 (4.29%)
At close: Sep 26, 2025, 4:00 PM EDT
0.3700
+0.0102 (2.83%)
After-hours: Sep 26, 2025, 7:59 PM EDT
Femasys Employees
As of December 31, 2024, Femasys had 71 total employees, including 69 full-time and 2 part-time employees. The number of employees increased by 37 or 108.82% compared to the previous year.
Employees
71
Change (1Y)
37
Growth (1Y)
108.82%
Revenue / Employee
$26,578
Profits / Employee
-$295,990
Market Cap
15.47M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
FEMY News
- 16 days ago - Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed® - GlobeNewsWire
- 19 days ago - Femasys Secures Regulatory Approval for FemBloc® Permanent Birth Control in New Zealand - GlobeNewsWire
- 4 weeks ago - Femasys Announces Pricing of $8.0 Million Underwritten Public Offering - GlobeNewsWire
- 7 weeks ago - Femasys Announces Second Quarter Financial Results for 2025 - GlobeNewsWire
- 7 weeks ago - Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion - GlobeNewsWire
- 3 months ago - Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic - GlobeNewsWire
- 3 months ago - Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control - GlobeNewsWire
- 3 months ago - Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth - GlobeNewsWire